Generic Breztri Aerosphere Availability
Last updated on Apr 10, 2025.
Breztri Aerosphere is a brand name of budesonide/formoterol/glycopyrrolate, approved by the FDA in the following formulation(s):
BREZTRI AEROSPHERE (budesonide; formoterol fumarate; glycopyrrolate - aerosol, metered;inhalation)
-
Manufacturer: ASTRAZENECA AB
Approval date: July 23, 2020
Strength(s): 0.16MG/INH;0.0048MG/INH;0.009MG/INH [RLD]
Is there a generic version of Breztri Aerosphere available?
No. There is currently no therapeutically equivalent version of Breztri Aerosphere available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Breztri Aerosphere. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
Patent 10,716,753
Issued: July 21, 2020
Inventor(s): Vehring Reinhard & Hartman Michael Steven & Smith Adrian Edward & Joshi Vidya B. & Dwivedi Sarvajna Kumar
Assignee(s): Pearl Therapeutics, Inc.Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting βadrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Patent expiration dates:
- May 28, 2030✓✓
- May 28, 2030
-
Drug delivery systems and related methods
Patent 11,331,442
Issued: May 17, 2022
Inventor(s): Ferriter; Matthew et al.
Assignee(s): Pearl Therapeutics, Inc. (Redwood City, CA)Systems and methods for isolating and/or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity.
Patent expiration dates:
- October 5, 2038✓
- October 5, 2038
-
Drug delivery systems and related methods
Patent 11,833,292
Issued: December 5, 2023
Inventor(s): Ferriter; Matthew et al.
Assignee(s): Pearl Therapeutics, Inc. (Redwood City, CA)Systems and methods for isolating and/or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity.
Patent expiration dates:
- October 5, 2038✓
- October 5, 2038
-
Compositions, methods and systems for respiratory delivery of two or more active agents
Patent 8,324,266
Issued: December 4, 2012
Inventor(s): Vehring Reinhard & Hartman Michael Steven & Lechuga-Ballesteros David & Smith Adrian Edward & Joshi Vidya B. & Dwivedi Sarvajna Kumar
Assignee(s): Pearl Therapeutics, Inc.Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Patent expiration dates:
- May 28, 2030✓
- May 28, 2030
-
Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
Patent 8,703,806
Issued: April 22, 2014
Inventor(s): Vehring Reinhard & Hartman Michael Steven & Lechuga-Ballesteros David & Smith Adrian Edward & Joshi Vidya B. & Dwivedi Sarvajna Jumar
Assignee(s): Pearl Therapeutics, Inc.Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Patent expiration dates:
- May 28, 2030✓
- May 28, 2030
-
Compositions for pulmonary delivery of long-acting βadrenergic receptor agonists and associated methods and systems
Patent 8,808,713
Issued: August 19, 2014
Inventor(s): Vehring Reinhard & Hartman Michael Steven & Smith Adrian Edward & Joshi Vidya B. & Dwivedi Sarvajna Kumar
Assignee(s): Pearl Thereapeutics, Inc.Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting βadrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Patent expiration dates:
- May 28, 2030✓✓
- May 28, 2030
-
Compositions, methods and systems for respiratory delivery of two or more active agents
Patent 8,815,258
Issued: August 26, 2014
Inventor(s): Vehring Reinhard & Hartman Michael Steven & Lechuga-Ballesteros David & Smith Adrian Edward & Joshi Vidya B. & Dwivedi Sarvajna Kumar
Assignee(s): Pearl Therapeutics, Inc.Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Patent expiration dates:
- March 17, 2031✓
- March 17, 2031
-
Compositions, methods and systems for respiratory delivery of two or more active agents
Patent 9,415,009
Issued: August 16, 2016
Inventor(s): Vehring Reinhard & Hartman Michael Steven & Lechuga-Ballesteros David & Smith Adrian Edward & Joshi Vidya B. & Dwivedi Sarvajna Kumar
Assignee(s): Pearl Therapeutics, Inc.Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Patent expiration dates:
- May 28, 2030✓
- May 28, 2030
-
Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
Patent 9,463,161
Issued: October 11, 2016
Inventor(s): Vehring Reinhard & Hartman Michael Steven & Smith Adrian Edward & Joshi Vidya B. & Dwivedi Sarvajna Kumar
Assignee(s): Pearl Therapeutics, Inc.Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting βadrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Patent expiration dates:
- May 28, 2030✓✓
- May 28, 2030
More about Breztri Aerosphere (budesonide / formoterol / glycopyrrolate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (120)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bronchodilator combinations
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
